← 홈

Antibody

1,230개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,230개
AntibodystaleRegeneronPhase 2

REGN15505+Cemiplimab (REGN15505+Cemiplimab)

Metastatic Castration-Resistant Prostate Cancer (mCRPC); Clear Cell Renal Cell Carcinoma (ccRCC) · Metastatic Castration-Resistant Prostate

#MetastaticCastration-ResistantPr#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleRegeneron PharmaceuticalsPhase 2

REGN17372+Linvoseltamab (REGN17372+Linvoseltamab)

Relapsed Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleSanofiPhase 2

REGN3500 + Dupilumab Combo (REGN3500 + Dupilumab Combo)

Atopic Dermatitis · Atopic Dermatitis

#AtopicDermatitis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleHoffmann-La RochePhase 1

RO5323441 + bevacizumab [Avastin] (RO5323441 + bevacizumab [Avastin])

Glioblastoma Multiforme · Glioblastoma Multiforme

#GlioblastomaMultiforme#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 1

atezolizumab (Tecentriq, RO7567132 and Atezolizumab)

Cancer-Neoplasms · Cancer-Neoplasms

#Cancer-Neoplasms#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAssociazione Volontari Pazienti…Phase 3

RT+CETUXIMAB (RT+CETUXIMAB)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleEli Lilly and CompanyPhase 1

IMC-1121B (Ramucirumab, Ramucirumab (IMC-1121B))

Colorectal Carcinoma · Colorectal Carcinoma

#ColorectalCarcinoma#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleJiangsu HengRui Medicine Co., L…Phase 3

Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan (Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan)

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma · HER2

#HER2#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleEli Lilly and CompanyPhase 2

Ramucirumab DP (Ramucirumab DP)

Carcinoma of Urinary Tract; Urethral Carcinoma · Carcinoma of Urinary Tract

#CarcinomaofUrinaryTract#Antibody#Phase2#항체#면역항체+3
효능 ORR 28.8%임상시험 1상태 ACTIVE
AntibodystaleImugene LimitedPhase 2

Ramucirumab plus Paclitaxel (Ramucirumab plus Paclitaxel)

Gastric Cancer; Cancer of Stomach · Gastric Cancer

#GastricCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleRochePhase 2

Recombinant Human Interleukin-2 and Rituximab (Recombinant Human Interleukin-2 and Rituximab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleTianjin Medical University Canc…Phase 2

Regorafenib and tislelizumab (Regorafenib and tislelizumab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAsan Medical CenterPhase 2

nivolumab (Opdivo, Regorafenib/Nivolumab)

Carcinoma, Hepatocellular; Hepatoma · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#Antibody#Phase2#항체#면역항체+5
효능 ORR 42%임상시험 1상태 ACTIVE
AntibodystaleWashington University School of…Phase 1

Relatilmab (Relatilmab)

Advanced Melanoma; Metastatic Melanoma · Advanced Melanoma

#AdvancedMelanoma#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Relatlimab FDC + Nivolumab)

Metastatic Triple-negative Breast Cancer · Metastatic Triple-negative Breast Cancer

#MetastaticTriple-negativeBreastC#Antibody#Phase2#항체#면역항체+2
효능 ORR 61.9%임상시험 1상태 RECRUITING
AntibodystaleLoyola UniversityPhase 2

infliximab (Remicaide, Remicaide (infliximab))

Toxic Epidermal Necrolysis · Toxic Epidermal Necrolysis

#ToxicEpidermalNecrolysis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleTevaPreclinical

Reslizumab (Reslizumab)

Asthma · Asthma

#Asthma#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleUniversity of Alabama at Birmin…Phase 1

Retifanlimab, INCAGN02385, INCAGN02390 (Retifanlimab, INCAGN02385, INCAGN02390)

Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase1#항체#면역항체+4
효능 ORR 100%임상시험 1상태 DISCONTINUED
AntibodystaleSWOG Cancer Research NetworkPreclinical

Rilotumumab (Rilotumumab)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#Antibody#Preclinical#항체#면역항체+3
효능 ORR 21%임상시험 1상태 ACTIVE

46 / 62 페이지

← 이전다음 →